Background: Anti-glomerular basement membrane (anti-GBM) disease is a rare autoimmune condition responsible for rapidly progressive glomerulonephritis. This disease is usually mediated by IgG autoantibodies against the noncollagenous domain of the α3(IV) collagen chain. In rare cases, IgA or IgM anti-GBM antibodies are involved. This raises the question of whether there are different types of antibody-mediated anti-GBM disease at the same time.

Case report: A 37-year-old woman with anti-GBM disease mediated by IgG and IgA. The patient developed rapidly progressive glomerulonephritis with nephrotic syndrome. Indirect immunofluorescence analysis indicated the presence of IgG and IgA antibodies reactive with a basement membrane component, identified by enzyme-linked immunoadsorbent assay and Western blotting as the α3(IV) collagen chain. After plasmapheresis and immunotherapy (steroids and cyclophosphamide), much improved the massive proteinuria and renal function. Follow up to date, she had normal renal function without proteinuria.

Conclusions: This is the first case report of anti-GBM disease mediated by IgG and IgA. If the clinical presentation and histopathological findings are suggestive of atypical anti-GBM disease, alternative laboratory tests such as Western blotting analysis can be used to confirm the diagnosis.

Introduction

Anti-glomerular basement membrane (anti-GBM) disease is a rare autoimmune condition responsible for rapidly progressive glomerulonephritis, which is mediated by circulating autoantibodies. The principal autoantigen is the α345 network of collagen IV, expression of which is restricted to target tissues [1]. Typically, linear deposition of immunoglobulin along the glomerular basement membrane (GBM) is seen. In most cases, the causative antibody is IgG [2,3]. Rarely, however, anti-GBM disease is mediated by immunoglobulin A (IgA) or immunoglobulin M (IgM) antibodies [4–7]. Here, we describe a new case of anti-GBM disease mediated by immunoglobulin G (IgG) and IgA.

Case report

A 37-year-old woman was admitted to the renal unit for rapidly progressive glomerulonephritis. Medical history included fracture of the left clavicle 10 years ago. She has no smoking or alcohol, no history of hydrocarbon exposure, chemicals or heavy metal exposure, etc. The results of physical examination on admission, including blood pressure (110/65 mmHg), were normal. Serum creatinine had risen from 72 μmol/L to 310 μmol/L over the past 2 weeks. Urinary examination disclosed microscopic hematuria and proteinuria within the nephrotic range (8.11 g/day). She had hypoproteinemia (albumin 24 g/L) with no anemia (hemoglobin 124 g/L). Routine ELISAs were positive for anti-GBM (104 RU/mL, normal range <20 RU/mL) (EA 1251-9601 G; Euroimmun Medizinische Labordiagnostika (China), Beijing, China). Tests for IgA anti-GBM were not available on admission. Other laboratory investigations showed normal C3 and C4 levels and negative anti-nuclear antibody, anti-phospholipid antibody, and anti-neutrophil cytoplasmic antibody (ANCA). Immunoglobulins G, M, and A were normal and no paraprotein was found in serum or urine. Ultrasound
showed normal kidneys. Computed tomography (CT) excluded alveolar hemorrhage.

Kidney biopsy was performed. Immunofluorescence analysis indicated bright capillary wall staining for IgA (2+ to 3+) (Figure 1(A)) and IgG (2+ to 3+) (Figure 1(B)). There was weakly capillary wall staining for κ and λ (+), and segmental staining for IgM (1+) and FRA (2+). C3, C1q, HbsAg, HbcAg, and HCV-Ag were negative. All the four IgG subclassed deposition along GBM were detected. There was bright capillary wall staining for IgG1 (2+ to 3+) and IgG3 (2+), and weakly capillary wall staining for IgG2 (+) and IgG4 (+). Light microscopy showed segmental fibrinoid necrosis in five of 36 glomeruli (Figure 1(C,D)), and fibrinoid necrosis with crescent formation in seven of 36 glomeruli (Figure 1(E)). Epithelial cell foot process fusion was present, and no electron-dense deposits were found by electron microscopy (Figure 1(F)). The findings of renal biopsy suggested anti-GBM disease.

Informed consent was obtained for analysis of the patient’s serum. One human serum sample was used as a negative control, and another serum sample from an IgG anti-GBM patient was used as a positive control. Human kidney cortex basement membranes and non-collagenous (NC1) hexamers of type IV collagen were prepared as described previously [8–11]. Another commercial ELISA kit (EA 1251-9601 G; Euroimmun Medizinische Labordiagnostika (China), Beijing, China) using bovine kidney α3 (IV) collagen NC1 domain as an antigen was used to detect the presence of IgG anti-GBM autoantibodies in the patient’s serum. The recombinant human α3 (IV)NC1 (2 μg/L) were coated into the 96-well plates at 4°C overnight. After blocking and washing, diluted blood samples (1:100) were added at 37°C for 60 min. After washing, horseradish peroxidase (HRP)-conjugated mouse anti-human IgA antibodies (Sigma-Aldrich, St. Louis, MO) diluted at 1:5000 were added at 37°C for 60 min. 3,3’,5,5’-Tetramethylbenzidine (TMB) liquid was applied as substrate and the color development was terminated by 1 mM sulfuric acid after 20 min. The plates were read at 450 nm and absorbance value of each sample was calculated. The patient’s serum contained IgA (82 RU/mL, normal range <20 RU/mL) and IgG (78 RU/mL, normal range <20 RU/mL) anti-GBM autoantibodies.

Further analysis was performed by Western blotting as described previously [12]. Briefly, recombinant human NC1 monomers were subjected to 12.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (SDS-PAGE) under non-reducing conditions and transferred onto a nitrocellulose membrane (Schleicher and Schuell, Kent, UK) using semi-dry blotting. The membrane was blocked in TBST buffer (0.01 mol/L Tris–HCl, pH 7.2, 0.15 mol/L NaCl, 0.1% Tween 20, 20 g/L skimmed milk) for 30 min at room temperature, incubated overnight with sera diluted 1:50 in TBST at 4°C, washed, and incubated with alkaline phosphatase-conjugated secondary antibodies (mouse anti-human IgA antibodies and goat anti-human IgG; 1:6000; Sigma-Aldrich, St. Louis, MO) for 1 h.
B. Z. ET AL.

Discussion

The diagnosis of anti-GBM disease requires demonstration of anti-GBM antibodies in either the serum or kidneys. A reliable, sensitive, and highly specific ELISA was detected, and high titers of antibodies are detected in almost all patients with anti-GBM disease at the time of active disease [13]. However, standard assays for circulating anti-GBM antibodies are designed to detect only IgG. Therefore, standard assays would yield a negative result for serum containing non-IgG anti-GBM antibodies. If other types of circulating antibodies, such as IgA or IgM are suspected, separate tests are required. As the accuracy of serological assays is variable, a kidney biopsy to confirm the diagnosis is recommended unless contraindicated [14]. The serum from this patient contained IgA and IgG anti-GBM autoantibodies at similar levels detectable by a commercial ELISA kit. In addition, the pathological findings also suggested anti-GBM disease.

Anti-GBM disease is a rare autoimmune disorder with an estimated incidence of <1 per million population [2]. The major class of anti-GBM autoantibody deposited along the GBM on kidney biopsies is IgG, with exceptionally rare reports of IgA or IgM classified as atypical anti-GBM disease [4]. Collagen IV is the main constituent of all basement membranes, a specialized form of extracellular matrix, which supports tissue integrity and plays roles in a number of key functions, including cell signaling, morphogenesis, and tissue regeneration [15]. Commonly, IgG anti-GBM antibodies bind to the α3 subunit of the NC1 domain of type IV collagen (α3(IV)NC1). In addition to the ubiquitous autoantibodies against α3 NC1, distinct antibodies specific for the α5 NC1 domain have also been detected [16]. We performed a further analysis of the IgA and IgG antibodies capable of binding to α3(IV)NC1 in our patient.

However, the pathophysiology of anti-GBM disease mediated by IgG and IgA is not entirely understood. Among the known IgA or IgG mediated anti-GBM diseases, most of the patients had some immune diseases, including Henoch-Schönlein purpura, Crohn’s disease, and systemic lupus erythematosus; on the other hand, the autoantigen might prove more to be heterogeneous: it belonged to α5 and α6 chains of type IV collagen [13]. In our case, there was no associated immune disease and no exacerbating factors or triggers, such as smoking, hydrocarbon exposure, chemicals or heavy metal exposure, etc. Hence, this form of IgG and IgA related condition should be considered a different disease.

At present, the standard therapy for anti-GBM disease is a combination of immunosuppression and plasma exchange. Poor renal outcome is commonly associated with high serum creatinine (>500 μmol/L), large numbers of glomerular crescents (50%) on renal biopsy, or a need for dialysis at presentation [17,18]. Fortunately, this patient did not have such poor

Figure 2. Western blotting analysis using purified human α(IV)NC1 as an antigen. Lane 1, negative control, serum from this patient + α5 (IV) collagen + rabbit anti-human IgG; lane 2, positive control, serum from an IgG anti-GBM GN patient + α3 (IV) collagen + rabbit anti-human IgG; lane 3, serum from this patient + α3 (IV) collagen + rabbit anti-human IgG; lane 4, serum from this patient + α3 (IV) collagen + rabbit anti-human IgA.

at room temperature. Antibody binding was detected using nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate as a substrate (Sigma-Aldrich, St. Louis, MO). The patient’s IgA and IgG were shown to bind to the NC1 domain of GBM collagen IV. Both IgA and IgG mainly targeted a 25-kDa antigen (α3(IV)NC1) (Figure 2).

The patient was treated with three sessions of pulse methylprednisolone (500 mg/day x three days), followed by oral prednisone (1 mg/kg/day) and cyclophosphamide (1 mg/kg/day). Plasmapheresis was performed every other day for a total of six times. After 2 weeks of treatment, serum creatinine level had decreased from 310 μmol/L to 83.4 μmol/L. The urinary protein level decreased to 4.15 g/day, and albumin increased to 33 g/L. Two months later, renal function was stable (serum creatinine 88 μmol/L, urine protein had further decreased to 1.12 g/day, and albumin had increased to 43 g/L. The urine protein level decreased to 0.46 g/day with stable creatinine level after 4 months. Fortunately, she had normal renal function (serum creatinine 88 μmol/L) without proteinuria (0.07 g/day) at last follow-up (4 years later). The patient was satisfied with the therapeutic effect, and the written informed consent was obtained from her.
prognostic factors, and achieved complete remission after intensive treatment. However, the patient presented RPGN and a nephrotic range of proteinuria, the electron microscopy showed a diffuse effacement of podocyte foot processes in preserved structured glomeruli. Is there any possibility of coexisted diseases as podocytopathy? Although there are relevant reports, minimal change disease superimposed on anti-GBM antibody positive glomerulonephritis [19,20]. It is only speculated by clinical and pathological characteristics. The mechanism is not clear, but the prognosis of these patients was better than that of typical anti-GBM disease. Therefore, from the available data, we cannot completely exclude the patient coexisted podocytopathy.

Conclusions
To our knowledge, this is the first report of anti-GBM disease mediated by IgG and IgA. The patient’s IgG and IgA autoantibodies targeted α3(IV)NC1. Glomerular lesions were not significantly different from classical IgG anti-GBM disease or other atypical anti-GBM disease. The patient responded well to conventional therapy and plasma exchange. On the other hand, conventional anti-GBM assays used in clinical practice would detect only IgG antibodies, but it may cause some missed diagnosis. If the clinical presentation and histopathological findings are suggestive of atypical anti-GBM disease, alternative laboratory tests such as Western blotting analysis can be used to confirm the diagnosis.

Acknowledgements
We thank the patient and clinicians involved in her care as well as the Institute of Nephrology, Peking University for their ongoing support. The written informed consent was obtained from the patient. We acknowledge Dr. Zhao Cui for assistance in providing purified human α3(IV)NC1 as an antigen.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
This work was financed by the National Key Clinical Specialty Capacity Building Project of China (Grant Number 2019-QTL-013).

References
[1] Pedchenko V, Kitching AR, Hudson BG. Goodpasture’s autoimmune disease – a collagen IV disorder. Matrix Biol. 2018;71–72:240–249.
[2] McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12(7):1162–1172.
[3] Henderson SR, Salama AD. Diagnostic and management challenges in Goodpasture’s (anti-glomerular basement membrane) disease. Nephrol Dial Transplant. 2018;33(2):196–202.
[4] Fervenza FC, Terreros D, Boutaud A, et al. Recurrent Goodpasture’s disease due to a monoclonal IgA-kappa circulating antibody. Am J Kidney Dis. 1999;34(3):549–555.
[5] Borza DB, Chedid MF, Colon S, et al. Recurrent Goodpasture’s disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen. Am J Kidney Dis. 2005;45(2):397–406.
[6] Nasr SH, Collins AB, Alexander MP, et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int. 2016;89(4):897–908.
[7] Bacalja J, Zibar L, Ljubanović DG. IgA-mediated anti-glomerular basement membrane disease. A case report. Nefrologia. 2018;38(3):339–341.
[8] Cui Z, Zhao MH, Singh AK, et al. Antiglomerular basement membrane disease with normal renal function. Kidney Int. 2007;72(11):1403–1408.
[9] Yang R, Cui Z, Hellmark T, et al. Natural anti-GBM antibodies from normal human sera recognize alpha3(IV)NC1 restrictively and recognize the same epitopes as anti-GBM antibodies from patients with anti-GBM disease. Clin Immunol. 2007;124(2):207–212.
[10] Nishibata Y, Masuda S, Nakazawa D, et al. Epitope recognized by anti-glomerular basement membrane (GBM) antibody in a patient with repeated relapse of anti-GBM disease. Exp Mol Pathol. 2019;107:165–170.
[11] Tan Y, Pang W, Jia X, et al. Comparison of the performance of a chemiluminescence assay and an ELISA for detection of anti-GBM antibodies. Ren Fail. 2020;42(1):48–53.
[12] Cui Z, Zhao MH, Jia XY, et al. Antibodies to α5 chain of collagen IV are pathogenic in Goodpasture’s disease. J Autoimmun. 2016;70:1–11.
[13] Moulis G, Huart A, Guitard J, et al. IgA-mediated anti-glomerular basement membrane disease: an uncommon mechanism of Goodpasture’s syndrome. Clin Kidney J. 2012;5(6):545–548.
[14] Wen YK, Wen KI. An unusual case of IgA-mediated anti-glomerular basement membrane disease. Int Urol Nephrol. 2013;45(4):1229–1234.
[15] Pozzi A, Yurchenco PD, Iozzo RV. The nature and biology of basement membranes. Matrix Biol. 2017;57–58:1–11.
[16] Pedchenko V, Bondar O, Fogo AB, et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N Engl J Med. 2010;363(4):343–354.
[17] Levy JB, Turner AN, Rees AJ, et al. Long-term outcome of anti-glomerular basement membrane antibody
disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134(11):1033–1042.

[18] van Daalen EE, Jennette JC, McAdoo SP, et al. Predicting outcome in patients with anti-GBM glomerulonephritis. Clin J Am Soc Nephrol. 2018;13(1):63–72.

[19] Shibata Y, Fukuoka K, Yokota R, et al. Nephrotic syndrome due to minimal-change disease superimposed on anti-glomerular basement membrane antibody positive glomerulonephritis; a case report. BMC Nephrol. 2020;21(1):283.

[20] Takeda Y, Abe A, Toki T, et al. Case of Goodpasture syndrome associated with minimal change nephrotic syndrome (MCNS) in a patient with rheumatoid arthritis (RA). Nihon Jinzo Gakkai Shi. 2009;51:897–903.